Cargando…
Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
Thromboembolic events (TEE) are a serious clinical problem in multiple myeloma (MM) patients receiving thalidomide (T). Thirty-one MM patients were tested on diagnosis and after 2 and 4 weeks of therapy with T alone, or T in combination with dexamethasone (TD). Closure time (CT) in PFA-100 and P-sel...
Autores principales: | Robak, Marta, Treliński, Jacek, Chojnowski, Krzysztof |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505549/ https://www.ncbi.nlm.nih.gov/pubmed/22772968 http://dx.doi.org/10.1007/s12032-012-0290-0 |
Ejemplares similares
-
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018) -
The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016) -
Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy
por: Treliński, Jacek, et al.
Publicado: (2012) -
Necrobiotic xanthogranuloma associated with smoldering multiple
myeloma: satisfactory response to cyclophosphamide, dexamethasone, and
thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019) -
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)